Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.
| Revenue (TTM) | $48.92B |
| Gross Profit (TTM) | $35.93B |
| EBITDA | $13.54B |
| Operating Margin | 21.00% |
| Return on Equity | 5.71% |
| Return on Assets | 5.09% |
| Revenue/Share (TTM) | $20.25 |
| Book Value | $32.33 |
| Price-to-Book | 1.28 |
| Price-to-Sales (TTM) | 1.97 |
| EV/Revenue | 2.174 |
| EV/EBITDA | 12.89 |
| Quarterly Earnings Growth (YoY) | -91.20% |
| Quarterly Revenue Growth (YoY) | 14.60% |
| Shares Outstanding | $2.40B |
| Float | $2.16B |
| % Insiders | 0.00% |
| % Institutions | 8.01% |
Volatility is currently contracting
Sanofi's upgraded 2026 outlook, Dupixent growth and attractive valuation give it an edge over AbbVie, despite pipeline setbacks and vaccine sales challenges.
Availability of the aide-mémoire for Q3 2026 results Paris, France – October 6, 2026. Sanofi announced today the availability of the aide-mémoire for Q3 2026 results on the "Investors" page of sanofi.com: Third quarter 2026 results Prepared each quarter, this document is intended to support financial modelling of the quarterly results.
Sanofi is carrying the Nuvaxovid COVID-19 shot into the fall vaccination season, and buyers are rewarding shares of licensor Novavax (NASDAQ:NVAX) far more heavily than the rest of biotech. Novavax stock has rose 17% during afternoon trading, reaching $12.
NEW YORK--(BUSINESS WIRE)--Weitz & Luxenberg, which represents more people in the Dupixent litigation than any other firm, appeared this past Friday at the first hearing in the federal multidistrict litigation over allegations that Dupixent (dupilumab) can cause, accelerate or unmask cutaneous T-cell lymphoma (CTCL). Judge Zahid N. Quraishi of the U.S. District Court for the District of New Jersey held the initial case management conference for In re: Dupixent (dupilumab) Products Liability.
SNY and REGN expand their longstanding alliance to four new antibodies targeting type II inflammation, with billions in potential payments.
Regeneron Pharmaceuticals NASDAQ: REGN and Sanofi said they are expanding their long-running collaboration to develop and commercialize next-generation medicines for type 2 inflammatory diseases, adding four Regeneron-originated antibody programs and establishing a new equal-sharing economic framework for the assets.
Regeneron and Sanofi NASDAQ: SNY announced an expanded collaboration focused on developing next-generation medicines for type 2 inflammatory diseases, extending an alliance that has produced the blockbuster therapy DUPIXENT.
The companies will share development and commercialization costs as well as potential future profits from the new drugs, they said.
French drugmaker Sanofi said on Thursday it would pay US partner Regeneron $1 billion upfront and up to $7 billion more in milestone payments to add four next-generation, long-acting immunology antibodies to the partnership behind their blockbuster eczema drug Dupixent.
Sanofi and Regeneron expand global Alliance with multiple nex t-generation, long-acting immunology antibodies REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the Alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-acting pre-clinical antibodies from Regeneron Regeneron to receive $1 billion upfront, with potential for up to an additional $7 billion in future milestone payments; companies to equally share development and commercialization costs, as well as any future profits Sanofi and Regeneron to host a conference call for investors and analysts today at 14:00 CET/8:00am ET Paris and Tarrytown, NY, October 1, 2026. Sanofi and Regeneron Pharmaceuticals, Inc. today announce an expansion of their longstanding antibody collaboration, adding multiple next-generation, long-acting antibodies to the Alliance that has jointly established Dupixent® (dupilumab) as the world-leading treatment for diseases driven by type 2 inflammation.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SNY and any ticker you trade — then tracks every position and per-strategy win rate.
